Rheumatology Advance Access originally published online on December 11, 2007
Rheumatology 2008 47(2):223-224; doi:10.1093/rheumatology/kem302
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
LETTERS TO THE EDITOR |
Sustained response to anakinra in ankylosing spondylitis
Academic Unit of Musculoskeletal Disease, Chapel Allerton Hospital, Leeds, UK
Correspondence to: D. McGonagle. E-mail: d.g.mcgonagle{at}leeds.ac.uk
SIR, We write with regard to the use of the interleukin-1 (IL-1) receptor antagonist, anakinra, in ankylosing spondylitis (AS). We previously reported a 3-month open-label study of anakinra in nine patients with active AS where clinical, laboratory parameter and MRI improvements were described [1] (Table 1). Six of the nine patients achieved Assessment in AS 20% (ASAS20) improvement and 61% of the identified regions of enthesitis/osteitis determined by MRI improved or regressed, but the changes appeared less dramatic than those evident on anti-tumour necrosis factor (TNF) agents.
|
Haibel et al. [2] subsequently reported a 24-week, open-label study of anakinra in 20 patients with AS. They reported non-significant decreases in Bath AS Disease Activity Index (BASDAI), an increase in C-reactive protein (CRP) and no improvement in MRI acute inflammatory lesions. However, 5 of the 13 patients who completed the study achieved an ASAS20 response and they concluded that a small subgroup had symptomatic improvement with anakinra.
One possibility that could account for these apparent differences in these studies is that anakinra has only a short duration of efficacy beyond which there is no benefit. We, therefore, reviewed three patients from our cohort, who continued anakinra therapy on compassionate grounds for a mean of 23 months (range 19–30). Two continued to respond until the drug was withdrawn, because of lack of funding, and one (Patient 3) lost efficacy after 19 months. Clinical and laboratory responses demonstrate sustained efficacy beyond 6 months in these cases (Table 1). Following therapy cessation, CRP values rose in all three cases. Subsequently, two of the patients switched to the anti-TNF fusion protein, etanercept, with good clinical and acute-phase response.
IL-1 is a pro-inflammatory cytokine that is central to inflammation and joint destruction, is up-regulated in spondyloarthropathies and claims for an IL-1 polymorphism in association with AS have been made [3–6]. Although there are conflicting results in open-label studies of the efficacy of anakinra in AS [1, 2], it is clear from both the studies that certain individuals respond to the drug for up to 24 weeks. In our three cases, the response was sustained for up to 30 months. It may be that patients with sustained response have a more IL-1-mediated disease than non-responders. Our cohort also had a 40% greater baseline CRP compared with the German cohort, indicating that higher serum markers of inflammation may be a predictor of response as has been suggested for anti-TNF response in AS [7]. Haibel et al. [2] reported that 21% of their cohort achieved ASAS40 response that is substantially greater than the reported placebo response of 5.1% in a previous AS anti-TNF study [8].
To summarize, we feel that the available data do not completely exclude a role for anakinra therapy in some cases of AS. It remains a strong possibility that the inflammation associated with AS may be amenable to IL-1 pathway modulation and it is possible that IL-1 blockade, either partially with anakinra or more completely with monoclonal antibodies, may have a role. Future trials will address these issues.
Disclosure statement: The authors have declared no conflicts of interest.
 |
References |
|---|
 Top References |
|---|
- Tan AL, Marzo-ortega H, O'Conner P, Fraser A, Emery P, McGonagle D. Efficacy of anakinra in active ankylosing spondylitis: a clinical and magnetic resonance imaging study. Ann Rheum Dis (2004) 63:1041–5.
[Abstract/Free Full Text] - Haibel M, Rudwaleit M, Listing J, Sieper J. Open label trial of anakinra in active ankylosing spondylitis over 24 weeks. Ann Rheum Dis (2005) 64:296–8.
[Abstract/Free Full Text] - McGarry F, Neilly J, Anderson. N, Sturrock R, Field M. A polymorphism within the interleukin 1 receptor antagonist (IL-1Ra) gene is associated with ankylosing spondylitis. Rheumatology (2001) 40:1359–64.
[Abstract/Free Full Text] - Danis V, March LM, Nelson DS, Brooks PM. Interleukin-1 secretion by peripheral blood monocytes and synovial macrophages from patients with rheumatoid arthritis. J Rheumatol (1987) 14:33–9.[Web of Science][Medline]
- Nouri A, Panayi GS, Goodman SM. Cytokines and the chronic inflammation of rheumatic disease. 1. The presence of interleukin-1 in synovial fluids. Clin Exp Immunol (1984) 55:295–302.[Web of Science][Medline]
- Vazaquez-Del M, Garcia-Gonzalez A, Munoz-Valle JF, et al. Interleukin 1 beta (IL-1beta), IL-10, tumor necrosis factor-alpha, and cellular proliferation index in peripheral blood mononuclear cells in patients with ankylosing spondylitis. J Rheumatol (2002) 29:522–6.
[Abstract/Free Full Text] - Rudwaleit M, Listing, Brandt J, Braun J, Seiper J. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis (2004) 63:665–70.
[Abstract/Free Full Text] - Braun JB, Brandt J, listing J, et al. Treatment of active ankylosing spondylitis with infliximab: a randomized controlled multicentre trial. Lancet (2002) 359:1187–93.[CrossRef][Web of Science][Medline]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. S. Yeap Comment on: NICE guidance does not tally with clinical practice--a district general experience Rheumatology, November 1, 2008; 47(11): 1735 - 1735. [Full Text] [PDF]
|
|
|
|
|
|
D. J. Pradeep, A. Keat, and K. Gaffney Predicting outcome in ankylosing spondylitis Rheumatology, July 1, 2008; 47(7): 942 - 945. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||